Direkt zum Inhalt
Merck
  • Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells.

Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells.

PloS one (2014-05-16)
Markus Fehrholz, Christian P Speer, Steffen Kunzmann
ZUSAMMENFASSUNG

Caffeine administration is an important part of the therapeutic treatment of bronchopulmonary dysplasia (BPD) in preterm infants. However, caffeine mediated effects on airway remodelling are still undefined. The TGF-β/Smad signalling pathway is one of the key pathways involved in airway remodelling. Connective tissue growth factor (CTGF), a downstream mediator of TGF-β, and transgelin, a binding and stabilising protein of the cytoskeleton, are both regulated by TGF-β1 and play an important role in airway remodelling. Both have also been implicated in the pathogenesis of BPD. The aim of the present study was to clarify whether caffeine, an unspecific phosphodiesterase (PDE) inhibitor, and rolipram, a prototypical PDE-4 selective inhibitor, were both able to affect TGF-β1-induced Smad signalling and CTGF/transgelin expression in lung epithelial cells. Furthermore, the effect of transgelin knock-down on Smad signalling was studied. The pharmacological effect of caffeine and rolipram on Smad signalling was investigated by means of a luciferase assay via transfection of a TGF-β1-inducible reporter plasmid in A549 cells. The regulation of CTGF and transgelin expression by caffeine and rolipram were studied by promoter analysis, real-time PCR and Western blot. Endogenous transgelin expression was down-regulated by lentiviral transduction mediating transgelin-specific shRNA expression. The addition of caffeine and rolipram inhibited TGF-β1 induced reporter gene activity in a concentration-related manner. They also antagonized the TGF-β1 induced up-regulation of CTGF and transgelin on the promoter-, the mRNA-, and the protein-level. Functional analysis showed that transgelin silencing reduced TGF-β1 induced Smad-signalling and CTGF induction in lung epithelial cells. The present study highlights possible new molecular mechanisms of caffeine and rolipram including an inhibition of Smad signalling and of TGF-β1 regulated genes involved in airway remodelling. An understanding of these mechanisms might help to explain the protective effects of caffeine in prevention of BPD and suggests rolipram to be a potent replacement for caffeine.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Phenylmethansulfonylfluorid, ≥98.5% (GC)
Sigma-Aldrich
Koffein, anhydrous, 99%, FCC, FG
Sigma-Aldrich
Phenylmethansulfonylfluorid, ≥99.0% (T)
Sigma-Aldrich
Koffein, powder, ReagentPlus®
Supelco
Koffein, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Koffein, United States Pharmacopeia (USP) Reference Standard
USP
Koffein-Schmelzpunkt-Standard, United States Pharmacopeia (USP) Reference Standard
Supelco
Coffein Schmelzpunktstandard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Rolipram, solid, ≥98% (HPLC)
Supelco
Koffein, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Koffein, Sigma Reference Standard, vial of 250 mg
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Sigma-Aldrich
Koffein, anhydrous, tested according to Ph. Eur.
Supelco
Mettler Toledo Calibration Substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
Koffein, meets USP testing specifications, anhydrous
Sigma-Aldrich
Koffein, BioXtra
Koffein, European Pharmacopoeia (EP) Reference Standard
Koffein für die Systemeignung, European Pharmacopoeia (EP) Reference Standard